2. Search Result
Search Result
Results for "

ICL

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Peptides

1

Recombinant Proteins

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17359
    Deferasirox
    Maximum Cited Publications
    13 Publications Verification

    ICL 670

    		 Bacterial Ferroptosis Cancer
    Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox
  • HY-103371
    DCPIB
    10+ Cited Publications

    		 Chloride Channel Potassium Channel Neurological Disease
    DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .
    DCPIB
  • HY-13703A
    Nimustine hydrochloride
    1 Publications Verification

    ACNU

    		 DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis p38 MAPK JNK AP-1 Cancer
    Nimustine hydrochloride (ACNU) is the hydrochloride salt form of Nimustine (HY-13703). Nimustine hydrochloride is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine hydrochloride activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
    Nimustine hydrochloride
  • HY-115840
    ICL-CCIC-0019

    		Apoptosis Cancer
    ICL-CCIC-0019 is an inhibitor of choline kinase α (CHKα). ICL-CCIC-0019 induces G1 block, endoplasmic reticulum stress apoptosis in cancer cell lines .
    ICL-CCIC-0019
  • HY-100468
    REV7/REV3L-IN-1
    1 Publications Verification

    		 DNA/RNA Synthesis Cancer
    REV7/REV3L-IN-1 is a REV7/REV3L interaction inhibitor with an IC50 of 78 μM, which directly binds to REV7 in nuclear magnetic resonance analyses, and inhibits the reactivation of a reporter plasmid containing an interstrand crosslink (ICL) in between the promoter and reporter regions .
    REV7/REV3L-IN-1
  • HY-116553
    FzM1

    		Wnt β-catenin Cancer
    FzM1 is a negative allosteric modulator (NAM) of Frizzled receptor FZD4. FzM1 reduces WNT5A-dependent WNT responsive element (WRE) activity (log EC50inh=?6.2). FzM1 binds to an allosteric binding site located in intracellular loop 3 (ICL3) of FZD4 and alters the conformation of the receptor, ultimately inhibiting the WNT/β-catenin cascade .
    FzM1
  • HY-171978A
    LM-189 free base

    		Adrenergic Receptor Cardiovascular Disease
    LM-189 free base, a G protein alpha subunit I (Gαi)-biased agonist, is a Gαi-biased ligand of β2-adrenergic receptor (β2AR). LM-189 free base stabilizes a distinct conformation in TM6 and increases the dynamics of ICL2. LM-189 free base can be used to develop the Gαi-biased β2AR agonists .
    LM-189 free base
  • HY-139621
    Colibactin 742

    		DNA Alkylator/Crosslinker Cancer
    Colibactin 742 is a covalently binding DNA-damaging agent targeting DNA, with an IC50 of 5.2 μM against human cervical cancer cells (HeLa). Colibactin 742 covalently binds to DNA, forming interstrand crosslinks (ICLs), activating the Fanconi anemia DNA repair pathway, inducing γH2AX and FANCD2 foci formation and cell cycle arrest, while exacerbating mismatch repair deficiency (MMRd)-related mutations. Colibactin 742 can mimic the genotoxicity of natural Colibactin while avoiding its instability, and is mainly used in colorectal cancer (CRC) related research, including microbial tumorigenesis mechanisms, DNA damage repair pathways, and mutation signature analysis .
    Colibactin 742
  • HY-171978
    LM-189

    		Adrenergic Receptor Cardiovascular Disease
    LM-189 is a β2-adrenergic receptor (β2AR) ligand and G protein-biased modulator with a human β2AR Ki of 0.063 nM.LM-189 promotes β2AR coupling to Gαs and Gαi heterotrimers, stabilizes distinct β2AR conformations including a TM6 outward state, and increases β2AR ICL2 dynamics.LM-189 restricts β2AR ligand-binding pocket conformational heterogeneity, stabilizes polar ligand-receptor interaction networks, and exhibits bias toward Gαi signaling over Gαs signaling.LM-189 enabled cryo-EM structural characterization of the β2AR-Gi complex.LM-189 can be used for the research of congestive heart failure .
    LM-189
  • HY-16581A
    DL-threo-2-methylisocitrate sodium
    1 Publications Verification

    		 Biochemical Assay Reagents Infection
    DL-threo-2-methylisocitrate sodium salt is a substrate of isocitrate lyase 1 (ICL1).
    DL-threo-2-methylisocitrate sodium
  • HY-149277
    FM04

    		P-glycoprotein Cancer
    FM04 is a potent P-glycoprotein (P-gp) inhibitor (EC50=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp .
    FM04
  • HY-17359R
    Deferasirox (Standard)

    ICL 670 (Standard)

    		 Reference Standards Bacterial Ferroptosis Cancer
    Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox (Standard)
  • HY-17359S
    Deferasirox-d4

    		Isotope-Labeled Compounds Bacterial Ferroptosis Cancer
    Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox-d4
  • HY-13703
    Nimustine

    		Apoptosis DNA Alkylator/Crosslinker DNA/RNA Synthesis p38 MAPK JNK AP-1 Cancer
    Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
    Nimustine
  • HY-113717
    ICL-SIRT078

    		Drug Derivative Others
    ICL-SIRT078 is an active compound.
    ICL-SIRT078
  • HY-17359S1
    Deferasirox-13C6

    ICL 670-13C6

    		 Isotope-Labeled Compounds Ferroptosis Bacterial Cancer
    Deferasirox- 13C6 (ICL 670- 13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox-13C6
  • HY-16581
    DL-threo-2-methylisocitrate

    		Others Infection
    DL-threo-2-methylisocitrate is a substrate of isocitrate lyase 1(ICL1).
    DL-threo-2-methylisocitrate
  • HY-121982
    Cyclo(L-Phe-L-Val)

    		Fungal Infection
    Cyclo(L-Phe-L-Val) is a potent inhibitor of enzymes isocitrate lyase (ICL) (IC50=27 μg/mL). cyclo(L-Phe-L-Val) inhibits the gene transcription of ICL in C. albicans under C2-carbon-utilizing conditions .
    Cyclo(L-Phe-L-Val)
  • HY-181771
    IDD-AN-A1

    		Bacterial Infection
    IDD-AN-A1 is a potent Mycobacterium tuberculosis (Mtb) isocitrate lyase (ICL) inhibitor with an IC50 of 7 μg/mL. IDD-AN-A1 shows additive and synergistic activity with anti-tuberculosis agents. , respectively.IDD-AN-A1 exhibits potent anti-tuberculosis activity. IDD-AN-A1 can be used for the research of tuberculosis .
    IDD-AN-A1
  • HY-103371R
    DCPIB (Standard)

    		Reference Standards Chloride Channel Potassium Channel Neurological Disease
    DCPIB (Standard) is the analytical standard of DCPIB (HY-103371). This product is intended for research and analytical applications. DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .
    DCPIB (Standard)
  • HY-100468R
    REV7/REV3L-IN-1 (Standard)

    		DNA/RNA Synthesis Reference Standards Cancer
    REV7/REV3L-IN-1 (Standard) is the analytical standard of REV7/REV3L-IN-1 (HY-100468). This product is intended for research and analytical applications. REV7/REV3L-IN-1 is a REV7/REV3L interaction inhibitor with an IC50 of 78 μM, which directly binds to REV7 in nuclear magnetic resonance analyses, and inhibits the reactivation of a reporter plasmid containing an interstrand crosslink (ICL) in between the promoter and reporter regions .
    REV7/REV3L-IN-1 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: